Interventional oncology company Delcath Systems Inc. (DCTH) is advancing toward a key milestone in its clinical and commercial trajectory with the upcoming oral presentation of data from the investigator-initiated CHOPIN Phase 2 trial at the 2025 European Society for Medical Oncology or ESMO Annual Congress.
The presentation will spotlight results from the investigator-initiated CHOPIN Phase 2 trial, a randomized study evaluating a novel combination therapy for metastatic uveal melanoma (mUM), a rare and aggressive form of eye cancer with limited treatment options.
Subscribe to continue reading the article.
This article is part of our premium content offering.Subscribe with a RTTNews subscription.
Subscribe NowAlready subscribed? Sign in
For comments and feedback: editorial@rttnews.com